Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials [Applied Biological Sciences]

Two phase 3 placebo-controlled trials of the CYD-TDV vaccine, evaluated in children aged 2−14 y (CYD14) and 9−16 y (CYD15), demonstrated vaccine efficacy (VE) of 56.5% and 60.8%, respectively, against symptomatic virologically confirmed dengue (VCD). Sieve analyses were conducted to evaluate whether and how VE varied with amino acid sequence...

https://ift.tt/2PAvlHK